Pertuzumab plus trastuzumab in metastatic breast cancer
- PMID: 22475602
- DOI: 10.1056/NEJMc1201462
Comment on
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.PMID: 22149875 Free PMC article. Clinical Trial.
Similar articles
-
Pertuzumab plus trastuzumab in metastatic breast cancer.N Engl J Med. 2012 Apr 5;366(14):1349; author reply 1349-50. doi: 10.1056/NEJMc1201462.PMID: 22475604 No abstract available.
-
Pertuzumab plus trastuzumab in metastatic breast cancer.N Engl J Med. 2012 Apr 5;366(14):1348-9; author reply 1349-50. doi: 10.1056/NEJMc1201462.PMID: 22475603 No abstract available.
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.PMID: 22149875 Free PMC article. Clinical Trial.
-
Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.Med Lett Drugs Ther. 2012 Jul 23;54(1395):59-60.PMID: 22825690 No abstract available.
-
Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12.PMID: 25494663 Review.
Cited by 2 articles
-
Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes.PLoS One. 2014 Sep 5;9(9):e106448. doi: 10.1371/journal.pone.0106448. eCollection 2014.PMID: 25192037 Free PMC article.
-
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Int J Womens Health. 2014 May 16;6:509-21. doi: 10.2147/IJWH.S47357. eCollection 2014.PMID: 24876795 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut – more resources
-
Full Text Sources
-
Medical
Source: https://pubmed.ncbi.nlm.nih.gov/22475602/